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To establish guidelines for the selenium supplementation in radiotherapy we assessed the benefits and risks of
selenium supplementation in radiotherapy. Clinical studies on the use of selenium in radiotherapy were searched in
the PubMed electronic database in January 2013. Sixteen clinical studies were identified among the 167 articles
selected in the initial search. Ten articles were observational studies, and the other 6 articles reported studies on the
effects of selenium supplementation in patients with cancer who underwent radiotherapy. The studies were
conducted worldwide including European, American and Asian countries between 1987 and 2012. Plasma, serum
or whole blood selenium levels were common parameters used to assess the effects of radiotherapy and the
selenium supplementation status. Selenium supplementation improved the general conditions of the patients,
improved their quality of life and reduced the side effects of radiotherapy. At the dose of selenium used in these
studies (200–500 μg/day), selenium supplementation did not reduce the effectiveness of radiotherapy, and no
toxicities were reported. Selenium supplementation may offer specific benefits for several types of cancer patients
who undergo radiotherapy. Because high-dose selenium and long-term supplementation may be unsafe due to
selenium toxicity, more evidence-based information and additional research are needed to ensure the therapeutic
benefits of selenium supplementation.
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Radiotherapy is one of the most common and effective
treatments for cancer [1]. Radiation damages cancer
cells by direct ionization of DNA and by indirect effects
caused by reactive oxygen species (ROS) [2]. Ionizing
radiation consists of electromagnetic radiations, including
X-rays and gamma rays, and particulate radiation such as
electrons, protons and neutrons [2]. Exposure to ionizing
radiation produces ROS in the tissue environment; includ-
ing hydroxyl radicals (the most damaging), superoxide
anion radicals and other oxidants such as hydrogen perox-
ide [2]. Although radiotherapy is effective in killing cancer
cells, ROS produced in radiotherapy may threaten the
integrity and survival of the surrounding normal cells and
may cause late side effects of radiotherapy [1-3]. The
administration of radioprotective agents, which are sup-
posed to scavenge radiation-induced radicals and reduce* Correspondence: hkoyama@health.gunma-u.ac.jp
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article, unless otherwise stated.the effects of radiation at an early stage, has been sug-
gested as one approach for prophylaxis of radiation effects
in normal tissues [4,5].
Selenium, a trace element, is an essential nutrient of
fundamental importance in human biology [6] and as a
preventive approach to ROS detoxification, which acti-
vates and stimulates the endogenous system [4,7,8]. Some
of the most fundamental cellular processes, such as DNA
synthesis, depend on the presence of selenium within the
catalytic site of thioredoxin reductases (TrxR) [9,10]. A
moderate deficiency of selenium has been linked to many
conditions, such as an increased risk of cancer, infections
and male infertility; a decrease in immune and thyroid
function; and several neurological conditions [6,9]. A
review paper reported that in prospective studies pub-
lished in the 1980s and early 1990s involving 8,000 to
11,000 individuals, low selenium status was associated
with significantly increased risks of cancer incidence
and mortality [6].
A number of mechanisms have been suggested to
explain the anti-cancer effects of selenium [11]. Seleniumtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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limit DNA damage, both of which are linked to cancer risk
[11]. Other cellular processes and molecular pathways that
may be involved in the anti-cancer effects of selenium are
the induction of phase II conjugating enzymes that detox-
ify carcinogens, enhancement of the immune response, an
increase in tumor-suppressor protein p53, inactivation of
protein kinase C (PKC), alterations in DNA methylation,
blockage of the cell cycle to allow DNA repair, induction
of apoptosis in cancer cells and inhibition of angiogenesis
[11]. In survey studies, selenium has been reported as
a complementary alternative medicine (CAM) used in
lung and prostate cancer patients undergoing radio-
therapy [12,13].
However, there are no guidelines on selenium supple-
mentation in radiotherapy which should consist of inclu-
sion and exclusion criteria for selenium supplementation,
applicable cancer types, dose of supplementation, chem-
ical form of selenium, duration of supplementation and
the possible side effects of supplementation in radiother-
apy. First, however, the benefits and risks of selenium use
in radiotherapy should be clarified, as such information is
still insufficient. Tabassum et al. [14] summarized the pro-
tective effect of selenium against prostate cancer and Fritz
et al. [15] reviewed the relationship between selenium and
lung cancer, suggesting positive effects of selenium in
radiotherapy. Dennert and Horneber reviewed two clinical
trials published in 2006 as a Cochrane database systematic
review, and the review was revised in 2011 with the
addition of one trial [16]. The subjects in the Cochrane
database systematic reviews were limited to those included
in randomized controlled trials; therefore, only 3 studies
were reviewed, yielding no clear evidence that selenium
supplements improve the side effects of cancer therapy
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Figure 1 Flowchart of the literature search.selenium and radiotherapy to provide evidence-based
information on the benefits and risks of selenium sup-
plementation to aid in the establishment of guidelines for
selenium supplementation in radiotherapy.Methodology
The flowchart of our literature search is shown in
Figure 1. Briefly, a PubMed electronic database search
using medical subject headings (MeSH) terms and the
keywords “selenium”, “radiation” and “therapy” in January
2013 yielded 167 articles, 16 of which were clinical studies
on selenium and radiotherapy. The detailed keyword
search was as follows: “selenium” [MeSH Terms] OR “sel-
enium” [All Fields]) AND (“radiotherapy” [Subheading]
OR “radiotherapy” [All Fields] OR (“radiation” [All Fields]
AND “therapy” [All Fields]) OR “radiation therapy” [All
Fields] OR “radiotherapy” [MeSH Terms] OR (“radiation”
[All Fields] AND “therapy” [All Fields]) OR “radiation
therapy” [All Fields]).Clinical studies on selenium and radiotherapy
Table 1 lists the 16 articles on selenium and radio-
therapy in clinical studies. The studies were conducted
worldwide, including European, American and Asian
countries, between 1987 and 2012. A total of 1303 pa-
tients undergoing radiotherapy participated in the studies.
Of the 16 articles, 10 articles were observational studies
investigating patients’ selenium levels before, during and/
or after radiotherapy, while the other 6 articles investi-
gated the effects of selenium supplementation studies on
cancer patients who underwent radiotherapy. The cancer
types investigated were upper gastrointestinal, breast,
lung, larynx, head and neck, non-Hodgkin lymphoma,
brain, oral, prostate and gynecological cancers.g
 (n=131):
es that were not in English (n=17)
 in cells (n=13)  




ients who underwent radiotherapy (n=10)




ium with other antioxidants (n=6)
 patients (n=2)
osis (n=1)
Table 1 Clinical studies on selenium and radiotherapy between 1987 and 2012
Study no. Reference Site of
research
Number of patients Study design Type of cancer/disease Radiotherapy delivery
method
1 Pothier et al. [17] USA n = 71 Observation
of Se levels
Upper gastrointestinal cancer Not mentioned
2 Antila et al. [18] Finland n = 24 Observation
of Se levels
Breast cancer Energy photons followed
by 6–12 MeV electrons
3 Piccinini et al. [19] Italy n = 66 Observation
of Se levels
Breast cancer (n = 38),
lung cancer (n = 28)
Not mentioned
4 Rostkowska-
Nadolska et al. [20]
Poland n = 78 Observation
of Se levels
carcinoma of the larynx X-Ray therapy
5 Yadav et al. [21] India n = 30 Observation
of Se levels
Head and neck cancer Not mentioned
6 Last et al. [22] UK n = 100 Observation
of Se levels
Non-Hodgkin’s lymphoma Not mentioned
7 Fraunholz et al. [23] Germany n = 224 Observation
of Se levels
Breast cancer (n = 94); cervical
csncer (n = 25); head and neck
cancer (n = 23); lung cancer
(n = 19); prostate (n = 13);
other (n = 50)
6-MV and/or 25-MV
photons generated
by a linear accelerator
8 Franca et al. [24] Brazil n = 209 Observation
of Se levels
Breast cancer Not mentioned
9 Zeng YC et al. [25] China n = 95 Observation
of Se levels




10 Eroglu C et al. [26] Turkey n = 47 Observation
of Se levels
Head and neck cancer Not mentioned
11 Pakdaman, [27] Germany n = 32 Se
supplementation
Brain tumor Not mentioned
12 Kiremidjian-Schumacher
et al. [28]
USA n = 33 supplemented




Head and neck cancer Not mentioned
13 Micke et al. [29] Germany n = 48 Se
supplementation
Secondary lymphedema a linear accelerator
with 6-MeV photons or
a 60Co treatment unit
14 Elango et al. [30] India n = 126 Se
supplementation




15 Muecke et al. [31] Germany n = 81 supplemented
(n = 39) control
group (n = 42)
Se
supplementation
Cervical cancer (n = 11);
uterine cancer (n = 70)
6- to 18-MV linear
accelerator
16 Buntzel et al. [32] Germany n = 39 Se
supplementation
Head and neck cancer Not mentioned
Total = 1303
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types of radiotherapy delivered to the patients, and in
most cases, electromagnetic radiations was used.
Observational studies
Table 2 presents the observational studies investigating
the selenium levels in patients who underwent radio-
therapy without selenium supplementation. In addition
to the 10 observational studies, 2 studies assessed selen-
ium levels in patients who did not received selenium
supplementation, who served as a placebo group and
control group in the selenium supplementation studies.Thus, a total of 12 studies measured the selenium levels
in patients who underwent radiotherapy without selen-
ium supplementation.
Selenium levels Selenium levels were determined in the
plasma, serum or whole blood using atomic absorption
spectrometry (AAS) in 9 studies, inductively coupled
plasma mass spectrometry (ICP-MS) in 2 studies and
a fluorometric method in 1 study. The measurements
were performed before radiotherapy, during radiother-
apy, at the end of therapy and at specific time points
Table 2 Observational studies investigating the selenium levels in patients who underwent radiotherapy without
selenium supplementation
Study no. Reference Sample Measurement
method













34.3 ↓ - - -
2 Antila et al. [18] Serum AAS 130.7* Middle of
therapy
124.4* 128.3* 2 weeks 126.7*
2 months 121.2*









Serum AAS 253.8** - - - 6 weeks 267.5**
5 Yadav et al. [21] Serum AAS 62.7 - - 61.0 1 year Cured:91.5
Residual
disease: 61.8
6 Last et al. [22] Serum ICP-MS 72.44* - - - - -
7 Fraunholz et al. [23] Whole blood AAS 75.64 - - 75.88 6 weeks 81.28
8 Franca et al. [24] Plasma AAS ≤60 years:101.8 - - ≤60 years:
58.1↓
- -
>60 years:65.2 >60 years:
33.7↓
9 Zeng YC et al. [25] Whole blood AAS 90.4 - - 56.3↓ - -’







94.38 - - 8th
weeks: 91.8
8 weeks 89.92
15 Muecke et al. [31] Whole blood
(control group)
AAS 63.2 50% of
therapy
67.3 61.4 6 weeks 69
↓ = significant decrease.
*1 μmol/l = 1 μg/l x 0.0127 [33].
**1 ppm = 1,000 μg/l.
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Effect of radiotherapy on selenium levels The results
of selenium levels in patients who underwent radiotherapy
without supplementation demonstrated that selenium
levels had a tendency to decrease after radiotherapy. In 7
studies (study No. 2, 4, 5, 7, 10, 12, and 15), the seleniumTable 3 Selenium levels in patients who underwent radiother
Study no. Reference Sample Measurement
method Befo
radioth










15 Muecke et al. [31] Whole
blood
AAS 65
↑ = increase.levels were not significantly different before and after ther-
apy, but in 3 studies (study No. 1, 8, and 9), the selenium
levels after therapy were significantly lower than those
before therapy.
Effect of selenium supplementation on selenium levels
Table 3 shows the selenium levels in the patients who
underwent radiotherapy with selenium supplementation.apy with selenium supplementation









- - 120 ↑ - -







93.2↑ 90.9 ↑ 6 weeks (without
supplemen-tation)
73.2
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plementation had a tendency to increase after radiotherapy.
However, the selenium levels decreased again at 8 weeks
(study No.12) and 6 weeks (study No.15) after the comple-
tion of radiotherapy without selenium supplementation.
Selenium supplementation studies
Table 4 provides a summary of selenium supplementation
studies. The selenium supplementation studies in patients
who underwent radiotherapy were conducted from 1998
to 2010. Different types of studies were conducted, includ-
ing a randomized double-blind placebo-controlled study
(study No. 12), a multicenter phase 3 trial (study No. 15),
and a randomized phase 2 study (study No.16).
Therapeutic form of selenium, dose and administra-
tion All of the studies of selenium supplementation in
patients who underwent radiotherapy used sodium selen-
ite as the form of selenium for supplementation. Sodium
selenite was administered orally in most studies (study
No. 12–16) and in physiological saline in another report.
The dose of supplementation by oral administration
ranged from 200 to 500 μg daily, or 1,000 μg daily by infu-
sion in physiological saline.
Parameters observed or measured To assess the effect-
iveness of selenium supplementation in radiotherapy, the
parameters measured or observed in the studies were
selenium levels in the serum, plasma or whole blood;
mineral elements in the blood and other blood parameters
(aspartate amino transferase (AST), alanine amino transfer-
ase (ALT), gamma glutamyl transpeptidase (γ-GTP) and
erythrocyte sedimentation rate (ESR)) [27]; immune func-
tion [28]; quality of life [29]; enzymatic and non-enzymatic
antioxidants [30]; and side effects [31,32].
Effects of selenium supplementation on therapy Most
of the studies revealed positive effects of selenium supple-
mentation on the general condition of the patients and
their quality of life. The effects of supplementation were
different depending on cancer type. No reduction in ef-
fectiveness of radiotherapy [31] and no selenium toxicities
or complications were reported in any of the supplemen-
tation studies.
Pakdaman (study No.11) reported that treatment with
sodium selenite in patients with brain tumors was well
tolerated by all patients and increased blood selenium
levels [27]. A significant diminution of symptoms of intra-
cranial pressure was achieved in 76% of patients after
sodium selenite treatment [27].
In the study by Kiremidjian-Schumacher et al. (study
No. 12), sodium selenite treatment was shown to signifi-
cantly enhance cell-mediated immune responsiveness in
head and neck cancer patients [28]. This outcome relatedto the ability of selenium to enhance the expression of
both the α- (p55) and β- (p70/75) subunits of the interleu-
kin-2 receptor (IL2-R), which resulted in a greater number
of high-affinity IL2-R/cells and enhanced proliferation and
differentiation in cytotoxic effector cells [28,34,35].
Micke et al. (study No. 13) demonstrated, using the vis-
ual analogue scale, that the self-assessment of the quality
of life of patients suffering from head and neck cancer
with lymphedema significantly improved after selenium
supplementation [29].
Elango et al. (study No. 14) found that supplementation
with selenium in oral cancer patients for 6 months may
help to increase the enzymatic (superoxide dismutase
(SOD), catalase (CAT), glutathione peroxidase (GPx),
Glutathione reductase (GRx), Glucose-6-phosphate dehy-
drogenase (G6PDH)) and non-enzymatic (glutathione (GSH),
vitamin E, vitamin C, vitamin A and ceruloplasmin) de-
fense systems. The mechanism of the increase in the activ-
ity of the enzymatic defense system is due to increased
GPx synthesis as a result of the enhanced de novo synthe-
sis of this enzyme in the erythroid precursors of red blood
cells [30].
Muecke et al. (study No. 15) reported that selenium
supplementation in cervical and uterine cancer patients
yielded significant prevention of diarrhea and thus im-
proved the quality of life [31]. The increased activity of
the protective intestinal GPx isoenzymes may be respon-
sible for these effects due to the enhanced neutralization
of radiation-induced hydroperoxides and free radicals in
the small intestinal mucosa included in the radiation
volume [31].
In the study by Büntzel et al. (study No.16) selenium
supplementation reduced the radiation-associated side-
effects of dysphagia developments in patients with head
and neck cancer patients [32].
Parameters used to assess the effect of radiotherapy on
selenium status
We found that the plasma, serum or whole blood selen-
ium levels were common parameters used to assess the
effect of radiotherapy on selenium status and the effect-
iveness of selenium supplementation. Selenium levels
had a tendency to decrease after radiotherapy and to in-
crease with selenium supplementation. The mechanism
of this decrease is still unclear [24,25]. Pothier et al. sug-
gested that poor dietary intake due to anorexia, nausea,
and obstruction, compounded by selenium loss from
vomiting, diarrhea, and malabsorption, probably played
a role in the decrease [17]. Radiotherapy and chemother-
apy, combined with the suboptimal nutrition of cancer
patients, may further aggravate the selenium deficiency
[24,31]. Muecke et al. highlighted that patients with higher
blood selenium levels had a better radiation tolerance,
without any effect on the survival data [31]. Therefore,
Table 4 Selenium supplementation studies in patients who underwent radiotherapy
Study no. Reference Type of
cancer/disease
Type of study Form of Se used
for supplementation
Dose (μg) Administration Items observed/measured Result




Mineral elements, Se and
other blood parameters
(AST, ALT, γ-GTP, ESR)
A significant diminution of
symptoms of intracranial pressure













Se in plasma, CTL, MLR, PHA Significantly enhanced cell-mediated
immune responsiveness
13 Micke et al. [29] Secondary
Lymphedema





Foldi and Miller scoring
and quality of life
Foldi and Miller score: more than
78% showed an improvement of
one stage or more









the enzymatic and non enzymatic
defense systems
15 Muecke et al. [31] Cervical cancer
(n = 11); Uterin
cancer (n = 70)
Multicenter,
phase 3 trial




Whole blood Se Statistically significant in reducing
the number of episode and severity
of RT-induced diarrhea
16 Buntzel et al. [32] Head and
neck (n = 39)
Randomized
phase II study




Side effect evaluation Reduced the development of
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that physicians take the selenium status into account be-
fore prescribing any anticancer therapy to their patients or
consider additional supplementation before therapy when
the current selenium status appears insufficient [24,31].
Sodium selenite supplementation
In the studies reviewed, sodium selenite was the only form
of selenium used for supplementation. In nature, selenium
exists in many forms. The most well studied forms are
selenomethionine (SeMet), sodium selenite, selenium me-
thylselenocysteine, 1,4,-phenylenebis (methylene) seleno-
cyanate (p-XSC), and methylseleninic acid (MSA) [15].
Selenomethionine and selenocysteine (SeCys) are found
predominantly in foods such as bread, cereals, nuts, meat,
fish, and other seafood [36]. In human antioxidant sys-
tems, selenium participates in the form of SeCys incorpo-
rated into the various selenoproteins [11,15]. There are at
least 25 known selenoproteins, including GPx, TrxR,
iodothyroninedeiodinase, and the selenoproteins P, W and
R [37]. The most abundant selenoproteins in the blood
are selenoprotein P, which accounts for approximately
50% of plasma selenium [36,38,39], and GPx, which ac-
counts for 10–30% of plasma selenium [36,39].
Sodium selenite, an inorganic form of selenium, was
used for supplementation because it can primarily improve
the expression of selenoproteins after specific incorpor-
ation as SeCys [31]. Sodium selenite also has high bio-
logical activity and availability in the body [28] and is
known to easily pass the blood–brain barrier [27]. It does
not raise the concentrations of nonspecific selenium-
containing proteins (e.g., selenium-albumin), which is in
contrast to other widely used organic selenium supple-
ments (e.g., selenomethionine) [31].
Selenium toxicity
The Food and Nutrition Board, Institute of Medicine,
suggested a recommended dietary allowance (RDA) of
selenium for both men and women of 55 μg (0.7 μmol)/
day [40]. The tolerable upper intake level (UL) of selen-
ium in adults is set at 400 μg (5.1 μmol)/day based on
the adverse effect of selenosis [40]. The results of our
review of supplementation studies revealed that selenium
supplementation doses ranging from 200–500 μg/day by
oral administration was well tolerated by all patients, and
no toxicities were reported. Selenium supplementation
increased the blood selenium level, improved the general
condition of patients, improved quality of life and pre-
vented or reduced the side effects of radiotherapy. Muecke
et al. [31] also implied that supplementation with sel-
enium neither interferes with the biological effects of
ionizing radiation nor protects tumor cells.
The Nutritional Prevention of Cancer (NPC) trial re-
ported that selenium supplementation in subjects, withhistories of non-melanoma skin cancers significantly de-
creased the incidence of lung cancer in patients with low
baseline selenium concentrations, but supplementation
did not significantly decrease this incidence among indi-
viduals in the overall population [41]. Therefore, selenium
supplementation may have benefits if the selenium is
administered to patients with low selenium levels.
High-dose selenium and long-term supplementation
may be ineffective and unsafe because selenium can be
toxic at high concentrations. The NPC trial also reported
an association between long-term selenium supplementa-
tion and an increased risk of diabetes [42]. A review paper
in 2006 [43] revealed that serum selenium levels ranging
from 400–30,000 μg/l were associated with acute toxicity
and that levels ranging from 500–1,400 μg/l were associ-
ated with chronic toxicity (mean normal serum selenium
level is 125 μg/l [44]).
Another high-dose selenium case consisting of the use
of a liquid dietary supplement containing 200 times the
labeled concentration of selenium was reported in the
United States [44]. Of the 201 cases identified in 10 states,
1 person was hospitalized. The median estimated dose of
selenium consumed was 41,749 μg/day. The frequently re-
ported symptoms included diarrhea (78%), fatigue (75%),
hair loss (72%), joint pain (70%), nail discoloration (61%)
and nausea (58%). The symptoms persisting 90 days or
longer included fingernail discoloration and loss (52%),
fatigue (35%), and hair loss (29%) [44].
Conclusion
This paper summarized 16 clinical studies on selenium
and radiotherapy conducted from 1987 to 2012. The
studies included 1303 cancer patients. To assess the selen-
ium status in patients before and after radiotherapy, the
plasma, serum or whole blood selenium level was a com-
mon parameter used to assess the effect of radiotherapy
on selenium status and the effectiveness of selenium
supplementation. Selenium supplementation increased
the blood selenium level, improved the general condition
of patients, improved quality of life, prevented or reduced
the side effects of radiotherapy and did not reduce
the effectiveness of radiotherapy or cause any toxicity.
The results of our summary suggest that selenium
supplementation in the form of sodium selenite at doses
ranging from 200–500 μg daily by oral administration may
offer benefits for head and neck cancer; head and neck
cancer with lymphedema; and oral, cervical and uterine
cancer patients who undergo radiotherapy and have low
selenium levels. In the future, further research and add-
itional evidence of the benefits of selenium supplementa-
tion in patients during radiotherapy are required to clarify
optimal dosing strategies in specific types of cancer and
the associated risks, to ensure therapeutic efficacy before it
can be recommended for broad clinical use.
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